Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes

Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes

Abstract Aims Left ventricular hypertrophy (LVH) has been associated with an increased risk of cardiovascular (CV) disease and linked to increased morbidity and mortality. In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), hypertension is common, and patients with these co‐morb...

Full description

Saved in:
Bibliographic Details
Main Authors: Gerasimos Filippatos, Stefan D. Anker, George L. Bakris, Peter Rossing, Luis M. Ruilope, Andrew J.S. Coats, Stephan vonHaehling, Piotr Ponikowski, Giuseppe M.C. Rosano, Meike Brinker, Alfredo E. Farjat, Luke Roberts, Bertram Pitt, the FIDELIO‐DKD and FIGARO‐DKD investigators
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:ESC Heart Failure
Subjects:
Cardiorenal outcomes
Chronic kidney disease
Finerenone
Hospitalization for heart failure
Left ventricular hypertrophy
Type 2 diabetes
Online Access:https://doi.org/10.1002/ehf2.14962
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.14962

Similar Items